

Original article

The RNA degradation pathway is involved in PPAR α -modulated anti-oral tumorigenesis

Nai-Wen Chang^{1,*}, Yi-Ping Huang²

¹Department of Biochemistry, College of Medicine, China Medical University, Taichung 404, Taiwan.

²Department of Physiology, College of Medicine, China Medical University, Taichung 404, Taiwan.

Received 17th of September, 2019 Accepted 2nd of October, 2019

© Author(s) 2019. This article is published with open access by China Medical University

Keywords:

Next-generation sequencing;
Oral cancer;
PPAR α ;
RNA degradation pathway

ABSTRACT

Background: The activation of peroxisome proliferator-activated receptor alpha (PPAR α) has been shown to reprogram tumor metabolism and exhibits great potential for treating anti-oral tumorigenesis.

Methods: In this study, we used a pathway-based strategy to explore possible functional pathways involved in the anticancer activity of PPAR α in oral cancer cells through next-generation sequencing (NGS) and bioinformatic approaches.

Results: We found that 3919 genes were upregulated and 1060 genes were downregulated through PPAR α activation. These genes were mainly involved in the proteasomal, mRNA surveillance, spliceosomal, RNA transport, and RNA degradation pathways, as indicated by GO and KEGG enrichment analysis. Importantly, a total of 13 upregulated genes in the RNA degradation pathway were identified including 3 core exosome factor genes (*RRP43*, *RRP42*, and *CSL4*), 2 TRAMP complex genes (*TRF4* and *Mtr4*), 2 exosome cofactor genes (*RRP6* and *MPP6*), 2 CCR4-NOT complex genes (*CNOT2* and *CNOT3*), 2 Ski complex genes (*SKI2* and *Ski3*), 1 decapping complex gene (*EDC4*), and 1 gene involved in 5' exoribonuclease activity (*XRNI*).

Conclusion: Our findings suggest that the activation of PPAR α to upregulate the RNA degradation pathway might provide a new strategy for oral cancer treatment.

1. Introduction

The diagnosis of oral cancer at an early stage provides an approximately 80% survival rate, while diagnosis at a late stage decreases the survival rate to 20% [1, 2]. The prognosis of patients is poor even after treatment with targeted and chemotherapeutic drugs [2]. Unfortunately, the molecular mechanisms underlying the recurrence of oral squamous cell carcinoma remain unclear.

Peroxisome proliferator-activated receptor alpha (PPAR α) is known to regulate the expression of genes involved in lipid and glucose metabolism, inflammatory/vascular pathways, and tumor activity [3-7]. Our previous studies showed that the activation of PPAR α through fenofibrate was involved in several anti-oral cancer activities in both animal and cell culture models including (a) the suppression of the development of the preneoplastic lesion into oral squamous cell carcinoma [8], (b) the downregulation of mTOR activity by TSC1/2-dependent signaling through the stimulation of AMPK and the repression of Akt [9, 10], (c) the regulation of the expression of genes related to mitochondrial energy metabolism [6], and (d) the inhibition of oral cancer cell

proliferation and the induction of metabolic reprogramming by switching the energy production way from the Warburg effect to mitochondrial oxidative phosphorylation [11]. Thus, we suggested that the mechanisms by which PPAR α activation suppressed tumor progression might modulate energy metabolism through the downregulation of the Warburg effect [11]. However, the functional evidence for the PPAR α response described above is limited to tumor metabolism and energy production. In PPAR α -mediated anti-oral tumorigenesis, it is possible that some oncogenic pathways or alterations have yet to be described.

Recently, several next-generation sequencing (NGS) studies of oral cancer have been conducted, and a number of gene mutations have been correlated with the risk of oral cancer [12, 13]. However, the method by which gene mutations modulate oral cancer behavior is mostly unknown. To explore the biological behavior of cancer, cancer cell lines are widely used as tools and provide a platform for further studies of cancer treatment and drug discovery. In this study, we used a pathway-based strategy to identify possible functional pathways involved in the anticancer

*Corresponding author. Department of Biochemistry, College of Medicine, China Medical University, No. 91, Hsueh-Shih Road, Taichung 404, Taiwan.

E-mail address: nwchang@mail.cmu.edu.tw (N.-W. Chang).

cer activity of PPAR α in oral cancer cells. SAS cells were treated with or without fenofibrate to activate PPAR α and were collected for next-generation sequencing studies.

2. Methods

2.1. Cell culture

The SAS human oral cancer cell line used in this study was authenticated using the Promega GenePrint 10 System by Genelabs (Taipei, Taiwan) to confirm that no contamination was found [9]. The SAS cells were treated with 0.1% DMSO (control group) or 50 μ M fenofibrate (PPAR α group) (Sigma-Aldrich Corp., USA) for 24 hours as previously described [9]. Then, the cells were collected for total RNA extraction and expression profiling. All data were collected from three independent experiments.

2.2. RNA extraction and sequencing

Total RNA from each sample was extracted using RNeasy Mini Kit (Qiagen) as previously described [14]. The quality of the extracted RNA was confirmed by an Agilent 2100 Bioanalyzer (Agilent Technologies) and a NanoDrop (Thermo Fisher Scientific Inc.), respectively. Next-generation sequencing library were prepared according to the manufacturer's protocol (NEBNext[®] Ultra[™] RNA Library Prep Kit, Illumina[®]) [14].

2.3. Quality control and expression analysis

To obtain high-quality and clean data, technical sequences with a lower quality were removed as previously described [14]. Gene expression calculation was performed with Cuffdiff (v 2.2.1), which calculated FPKM (fragments per kilobases per million reads) [14]. The expression levels of all genes under different experimental conditions were compared by FPKM profiles.

2.4. Differential expression analysis

The DESeq Bioconductor package, which uses a model based on a negative binomial distribution, was used for differential expression analysis as previously described [15, 16]. The results from DESeq2 analysis were further analyzed to identify genes exhibiting significant differential expression according to the criteria of a fold change greater than 2 and a FDR (false discovery rate) less than 0.05. After adjustment by Benjamini and Hochberg's approach to control for the FDR, the Wald test was used to analyze the differences. Differences were considered significant at $P < 0.05$ [14].

2.5. GO and KEGG enrichment analysis

We first used GO (Gene Ontology) analysis to map all the differentially expressed genes to the GO database and then calculated the number of differential genes for each term. The GO terms enriched in differential genes were determined using a hypergeometric test against the genomic background. In addition, the KEGG (Kyoto Encyclopedia of Genes and Genomes) is a collection of databases that involve chemical substances, drugs, genomes, biological pathways, and diseases [17]. Pathway enrichment analysis was based on KEGG pathway units and used a hypergeometric test to find which pathways were significantly enriched for differentially expressed genes against the transcriptome background.




Fig. 1 - Flowchart of the study design. The SAS cells were treated with 0.1% DMSO (control) or 50 μ M fenofibrate for 24 hours. Then, the cells were collected for total RNA extraction and expression profiling. The results from DESeq2 analysis were further analyzed to identify genes with significantly differential expression according to the criteria of a fold change greater than 2 and a false discovery rate less than 0.05. Differentially expressed genes were selected for further cluster, GO, and KEGG enrichment analysis.

Differences were considered significant at $P < 0.05$.

3. Results

3.1. Determination of differential gene expression

The RNA expression profiles following PPAR α activation in SAS cells were obtained from NGS. The workflow of the analysis is summarized in Fig. 1. The results from DESeq2 analysis were further analyzed to identify genes exhibiting significantly differential expression according to the criteria of a fold change greater than 2 and a FDR less than 0.05. Gene expression in the control group was used as a baseline to determine the up- or downregulation of gene expression in PPAR α -induced cells. We found that 3919 genes were upregulated and 1060 genes were downregulated following PPAR α activation (Fig. 2A). The numbers of differentially expressed genes are displayed as a volcano plot in Fig. 2B.

3.2. GO classification of differentially expressed genes

Next, a total of 4979 differentially expressed mRNAs between the




Fig. 4 - Scatter plot of differential gene KEGG enrichment. The X-axis indicates the Rich factor. The Y-axis specifies the KEGG pathways. The size of the dot is positively correlated with the number of differentially expressed genes in the pathway. Color coding indicates different q value ranges. The Rich factor indicates the ratio of the number of differentially expressed genes in the pathway to the total number of genes in the pathway. A greater Rich factor indicates a greater degree of enrichment. The Q value is the P value after multiple hypothesis testing and ranges between 0 and 1; the closer the Q value is to zero, the more significant the enrichment is.

dant subcategories were catalytic activity and cofactor binding. The top 5 most prominent enrichment subcategories involved in the biological process category were cellular processes, biological regulation, single-organism processes, metabolic processes, and developmental processes. In the cellular component category, the most abundant subcategories were cell parts, organelles, organelle parts, and macromolecular complexes.

3.3. Scatter plot of differential gene KEGG enrichment

To understand the mechanism of the differential expression of the mRNAs described above, we implemented KEGG pathway enrichment analysis. The degree of KEGG enrichment was evaluated by the q value, the rich factor, and the number of genes enriched in the pathway [17]. The top 30 pathways with the most significant enrichment after screening are listed in Fig. 4. Remarkably, these mRNAs were enriched in the proteasomal, mRNA surveillance, spliceosomal, RNA transport, and RNA degradation pathways.

3.4. Upregulated genes involved in the RNA degradation pathway through PPAR α activation

It is known that mRNA degradation pathway plays a crucial role in cancer gene expression and cellular functions [18, 19]. The eukaryotic RNA exosome catalyzes RNA degradation and cooperates with cofactors such as TRAMP, CCR4-NOT, and Ski complexes to specifically target transcripts for 3' to 5' degradation, while 5' to 3' mRNA degradation is initiated by decapping complexes [20, 21]. We next identified genes in the RNA degradation pathway that exhibited significantly differential expression, which are shown in Table 1. According to the criteria of a fold change greater than 2 and a FDR less than 0.05, a total of 13 upregulated genes were identified in PPAR α -induced cells. We found that 3 core exosome factor genes (*RRP43*, *RRP42*, and *CSL4*), 2 TRAMP complex genes (*TRF4* and *Mtr4*), 2 exosome cofactor genes (*RRP6* and *MPP6*), 2 CCR4-NOT complex genes (*CNOT2* and *CNOT3*), and 2 Ski complex genes (*SKI2*, and *Ski3*) were involved in 3' to 5' mRNA degradation. In addition, the *EDC4* and

Table 1 — List of upregulated genes in the mRNA degradation pathway following PPAR α activation.

Gene Id	Gene Name	Log2 Fold Change	P-value Adjusted ^a	KEGG BRIT(mRNA Degradation Factors)	Localization
3'→5' decay					
ENSG00000120699	<i>RRP43, EXOSC8</i>	1.216	0.0003653	Core exosome factor	Nucleus/Cytoplasm
ENSG00000075914	<i>RRP42, EXOSC7</i>	1.028	0.0013357	Core exosome factor	Nucleus/Cytoplasm
ENSG00000171311	<i>CSL4, EXOSC1</i>	1.348	0.0003653	Core exosome factor	Nucleus/Cytoplasm
ENSG00000112941	<i>TRF4, PAPD7</i>	2.015	0.0003653	TRAMP complex	Nucleus
ENSG00000039123	<i>Mtr4, SKIV2L2</i>	1.727	0.0325274	TRAMP complex	Nucleus
ENSG00000171824	<i>RRP6, EXOSC10</i>	2.019	0.0003653	Exosome cofactor	Nucleus/Cytoplasm
ENSG00000135698	<i>MPP6, MPHOSPH6</i>	1.119	0.0075373	Exosome cofactor	Nucleus
ENSG00000111596	<i>CNOT2, NOT2</i>	2.235	0.0003653	Ccr4-NOT complex	Cytoplasm
ENSG00000088038	<i>CNOT3, NOT3</i>	1.839	0.0003653	Ccr4-NOT complex	Cytoplasm
ENSG00000204351	<i>SKI2, SKIV2L</i>	1.773	0.0019390	Ski complex	Cytoplasm
ENSG00000198677	<i>Ski3, TTC37</i>	1.385	0.0003653	Ski complex	Cytoplasm
5'→3' decay					
ENSG00000038358	<i>EDC4</i>	1.443	0.0062746	Decapping complex	Cytoplasm
ENSG00000114127	<i>XRNI, SEPI</i>	2.397	0.0298322	5' Exoribonuclease	Cytoplasm

^aP-value is adjusted for multiple testing using Benjamini and Hochberg's approach to estimate the false discovery rate.

XRNI genes were involved in 5' to 3' mRNA degradation.

4. Discussion

Our previous studies suggested an important role for PPAR α in anti-oral cancer activity in both animal and cell culture models [8, 9]. In this study, a next-generation sequencing approach was used to determine differentially expressed genes in PPAR α -induced SAS cells. The results showed that 3919 genes were upregulated and 1060 genes were downregulated through PPAR α induction, and these genes were mainly involved in the proteasomal, mRNA surveillance, spliceosomal, RNA transport, and RNA degradation pathways, as shown by GO and KEGG enrichment analysis. Among the 5 candidate pathways, the relationship between the RNA degradation pathway and oral tumor progression remains unclear. Therefore, we selected the RNA degradation pathway for further analysis.

It is known that exosomes mediate communication within the tumor microenvironment and play important roles in tumor development, invasion, and metastasis [22, 23]. Therefore, targeting RNA degradation pathways by blocking the RNA exosome and its cofactors could be a critical strategy in oral cancer therapy. In this study, we confirmed that the mRNA degradation pathway might be involved in PPAR α -induced anticancer activity. A total of 13 upregulated genes were identified in the RNA degradation pathway including 3 core exosome factor genes (*RRP43*, *RRP42*, and *CSL4*), 2 TRAMP complex genes (*TRF4* and *Mtr4*), 2 exosome cofactor genes (*RRP6* and *MPP6*), 2 CCR4-NOT complex genes (*CNOT2* and *CNOT3*), 2 Ski complex genes (*SKI2* and *Ski3*), 1 decapping complex gene (*EDC4*), and 1 gene involved in 5' exoribonuclease activity (*XRNI*).

The eukaryotic RNA exosome can degrade or process RNA substrates in the 3' to 5' direction [24, 25]. The core of the RNA exosome complex is composed of three S1/KH RNA-binding proteins (*CSL4*, *RRP4*, and *RRP40*) and six RNase PH-like proteins

(*MTR3*, *RRP41*, *RRP42*, *RRP43*, *RRP45*, and *RRP46*) [26, 27]. The loss of any one subunit of the nine genes listed above is lethal [26]. Our study showed the significant upregulation of the expression levels of *RRP43*, *RRP42*, and *CSL4* in PPAR α -induced cells. Although the molecular mechanisms for this remain unclear, mutations in the RNA exosome gene *RRP43* (*EXOSC8*) have been shown to be associated with pontocerebellar hypoplasia type 1c [28].

The eukaryotic RNA exosome functions in both the cytoplasm and the nucleus [21, 28]. Nuclear RNA exosomes can cooperate with cofactors such as the TRAMP complex (*Trf4/5-Air1/2-Mtr4* polyadenylation), *MPP6*, *RRP6*, and the NNS complex (*Nrd1-Nab3-Sen1*) to perform RNA degradation [21, 28]. Our study showed that PPAR α significantly upregulated the expression levels of the *TRF4*, *Mtr4*, *RRP6*, and *MPP6* genes, all four of which are known to be related to the RNA degradation pathway. Such differences provided a link between the exosomal contents and tumor progression. Recently, the *MPP6* protein was reported to regulate the protumorigenic activity of *SAA3*, a member of the serum amyloid A apolipoprotein family, in pancreatic ductal adenocarcinoma [29].

The cytoplasmic mRNA degradation pathway begins with removing the poly(A) tail by the CCR4-NOT complex [30], followed by the degradation of the mRNA in the 3' to 5' or 5' to 3' directions. The nine core subunits of the CCR4-NOT complex are *CNOT1*, *CNOT2*, *CNOT3*, *CNOT6*, *CNOT6L*, *CNOT7*, *CNOT8*, *CNOT9*, and *CNOT10* [31, 32]. Its biological functions are involved in regulation of mRNA stability, transcription, and translation [33, 34]. Our study showed that the *CNOT2* and *CNOT3* genes were upregulated by PPAR α activation and that their expression might promote the anticancer activity of PPAR α . Although how *CNOT2* and *CNOT3* function in the catalytic subunit during the oral cancer process remains unclear, a mutation in *CNOT3* is associated with non-small cell lung cancer and T-cell acute lymphoblastic leukemia [35, 36]. Studies from a breast cancer mouse model and human patient data demonstrate a nega-

tive correlation between *CNOT2* expression and tumor development and the CCR4-NOT complex was implicated in tumor cell metastasis [37, 38]. In addition, cytoplasmic mRNA degradation in the 3' to 5' direction is mainly catalyzed by exosomes and their cofactors such as the Ski complex (Ski2–Ski3–Ski8) and Ski7 [21, 28, 39]. In this study, we observed the upregulation of the *SKI2* and *Ski3* genes following PPAR α activation. Mutations in the *SKI2* and *Ski3* genes have been shown to be associated with syndromic diarrhea/trichohepatoenteric syndrome [40, 41].

Finally, we confirmed that the expression levels of the *EDC4* and *XRNI* genes, which are involved in 5' to 3' RNA decay, were upregulated by PPAR α . The mRNA degradation in the 5' to 3' direction is initiated by the decapping protein EDC4, and the mRNA is subsequently degraded by the exoribonuclease XRNI [20, 42]. Zangari *et al.* showed that, in mammals, the XRNI exoribonuclease specifically targets extracellular miR-223-3p and promotes transient epithelial-mesenchymal transition in human tumor cells [43].

Very little information is currently available concerning the degradation of mRNAs and oral cancer progression. The role of PPAR α in the direct regulation of the mRNA degradation pathway is still unclear. Further studies are needed to explore the specificity of the effect of PPAR α activation on the expression of genes involved in the RNA degradation pathway with PPAR α knockdown or pretreatment with PPAR α antagonists. Nevertheless, the identification of PPAR α -targeted genes in the RNA degradation pathway may help to highlight treatment strategies for oral cancer.

In conclusion, next-generation sequencing analysis revealed that a total of 13 genes (*RRP43*, *RRP42*, *CSL4*, *TRF4*, *Mtr4*, *RRP6*, *MPP6*, *CNOT2*, *CNOT3*, *SKI2*, *Ski3*, *EDC4*, and *XRNI*) involved in the mRNA degradation pathway were upregulated by PPAR α activation in oral cancer cells. Therefore, we suggest that the activation of PPAR α to enhance the mRNA degradation pathway might provide a new strategy for oral cancer therapy.

Acknowledgements

This work was supported by the China Medical University, Taiwan, ROC (grant number CMU106-S-09).

Conflicts of interest statement

The authors wish to disclose no conflicts of interest.

Open Access This article is distributed under terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided original author(s) and source are credited.

REFERENCES

[1] Karnov KKS, Grønhoj C, Jensen DH, Wessel I, Charabi BW, Specht L, *et al.* Increasing incidence and survival in oral cancer: a nationwide Danish study from 1980 to 2014. *Acta Oncol.* 2017; 56:

1204-9.
 [2] Seema S, Krishnan M, Harith AK, Sahai K, Iyer SR, Arora V, *et al.* Laser ionization mass spectrometry in oral squamous cell carcinoma. *J Oral Pathol Med.* 2014; 43: 471-83.
 [3] Finck BN, Kelly DP. Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. *J Mol Cell Cardiol.* 2002; 34: 1249-57.
 [4] Fruchart JC. Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. *Am J Cardiol.* 2001; 88: 24N-9N.
 [5] Grabacka M, Pierzchalska M, Reiss K. Peroxisome proliferator activated receptor α ligands as anticancer drugs targeting mitochondrial metabolism. *Curr Pharm Biotechnol.* 2013; 14: 342-56.
 [6] Huang YP, Chang NW. PPAR α modulates gene expression profiles of mitochondrial energy metabolism in oral tumorigenesis. *Bio-medicine (Taipei).* 2016; 6: 3.
 [7] Varet J, Vincent L, Mirshahi P, Pille JV, Legrand E, Opolon P, *et al.* Fenofibrate inhibits angiogenesis *in vitro* and *in vivo*. *Cell Mol Life Sci.* 2003; 60: 810-9.
 [8] Chang NW, Tsai MH, Lin C, Hsu HT, Chu PY, Yeh CM, *et al.* Fenofibrate exhibits a high potential to suppress the formation of squamous cell carcinoma in an oral-specific 4-nitroquinoline 1-oxide/arecoline mouse model. *Biochim Biophys Acta.* 2011; 1812: 558-64.
 [9] Jan CI, Tsai MH, Chiu CF, Huang YP, Liu CJ, Chang NW. Fenofibrate suppresses oral tumorigenesis *via* reprogramming metabolic processes: potential drug repurposing for oral cancer. *Int J Biol Sci.* 2016; 12: 786-98.
 [10] Tsai SC, Tsai MH, Chiu CF, Lu CC, Kuo SC, Chang NW, *et al.* AMPK-dependent signaling modulates the suppression of invasion and migration by fenofibrate in CAL 27 oral cancer cells through NF- κ B pathway. *Environ Toxicol.* 2016; 31: 866-76.
 [11] Huang YP, Chang NW. Proteomic analysis of oral cancer reveals new potential therapeutic targets involved in the Warburg effect. *Clin Exp Pharmacol Physiol.* 2017; 44: 880-7.
 [12] Ma J, Fu Y, Tu YY, Liu Y, Tan YR, Ju WT, *et al.* Mutation allele frequency threshold does not affect prognostic analysis using next-generation sequencing in oral squamous cell carcinoma. *BMC Cancer.* 2018; 18: 758.
 [13] Nakagaki T, Tamura M, Kobashi K, Omori A, Koyama R, Idogawa M, *et al.* Targeted next-generation sequencing of 50 cancer-related genes in Japanese patients with oral squamous cell carcinoma. *Tumour Biol.* 2018; 40: 1010428318800180.
 [14] Kan F, Ye L, Yan T, Cao J, Zheng J, Li W. Proteomic and transcriptomic studies of HBV-associated liver fibrosis of an AAV-HBV-infected mouse model. *BMC Genomics.* 2017; 18: 641.
 [15] Chhangawala S, Rudy G, Mason CE, Rosenfeld JA. The impact of read length on quantification of differentially expressed genes and splice junction detection. *Genome Biol.* 2015; 16: 131.
 [16] Hart T, Komori HK, LaMere S, Podshivalova K, Salomon DR. Finding the active genes in deep RNA-seq gene expression studies. *BMC Genomics.* 2013; 14: 778.
 [17] Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Res.* 2017; 45: D353-61.
 [18] Brewer G. Messenger RNA decay during aging and development.

Ageing Res Rev. 2002; 1: 607-25.

- [19] Burgess HM, Mohr I. Cellular 5'-3' mRNA exonuclease Xrn1 controls double-stranded RNA accumulation and anti-viral responses. *Cell Host Microbe*. 2015; 17: 332-44.
- [20] Franks TM, Lykke-Andersen J. The control of mRNA decapping and P-body formation. *Mol Cell*. 2008; 32: 605-15.
- [21] Zinder JC, Lima CD. Targeting RNA for processing or destruction by the eukaryotic RNA exosome and its cofactors. *Genes Dev*. 2017; 31: 88-100.
- [22] Suchorska WM, Lach MS. The role of exosomes in tumor progression and metastasis (Review). *Oncol Rep*. 2016; 35: 1237-44.
- [23] Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, *et al*. Role of tumor microenvironment in tumorigenesis. *J Cancer*. 2017; 8: 761-73.
- [24] Januszuk K, Lima CD. The eukaryotic RNA exosome. *Curr Opin Struct Biol*. 2014; 24: 132-40.
- [25] Kilchert C, Wittmann S, Vasiljeva L. The regulation and functions of the nuclear RNA exosome complex. *Nat Rev Mol Cell Biol*. 2016; 17: 227-39.
- [26] Liu Q, Greimann JC, Lima CD. Reconstitution, activities, and structure of the eukaryotic RNA exosome. *Cell*. 2006; 127: 1223-37.
- [27] Makino DL, Baumgärtner M, Conti E. Crystal structure of an RNA-bound 11-subunit eukaryotic exosome complex. *Nature*. 2013; 495: 70-5.
- [28] Morton DJ, Kuiper EG, Jones SK, Leung SW, Corbett AH, Fasken MB. The RNA exosome and RNA exosome-linked disease. *RNA*. 2018; 24: 127-42.
- [29] Djurec M, Graña O, Lee A, Troulé K, Espinet E, Cabras L, *et al*. Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors. *Proc Natl Acad Sci U S A*. 2018; 115: E1147-56.
- [30] Balagopal V, Fluch L, Nissan T. Ways and means of eukaryotic mRNA decay. *Biochim Biophys Acta*. 2012; 1819 : 593-603.
- [31] Collart MA, Panasenko OO. The Ccr4-not complex. *Gene*. 2012; 492: 42-53.
- [32] Rodríguez-Gil A, Ritter O, Saul VV, Wilhelm J, Yang CY, Grosschedl R, *et al*. The CCR4-NOT complex contributes to repression of Major Histocompatibility Complex class II transcription. *Sci Rep*. 2017; 7: 3547.
- [33] Chekulaeva M, Mathys H, Zipprich JT, Attig J, Colic M, Parker R, *et al*. miRNA repression involves GW182-mediated recruitment of CCR4-NOT through conserved W-containing motifs. *Nat Struct Mol Biol*. 2011; 18: 1218-26.
- [34] Zhang X, Virtanen A, Kleiman FE. To polyadenylate or to deadenylate: that is the question. *Cell Cycle*. 2010; 9: 4437-49.
- [35] De Keersmaecker K, Atak ZK, Li N, Vicente C, Patchett S, Girardi T, *et al*. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. *Nat Genet*. 2013; 45: 186-90.
- [36] Shirai YT, Mizutani A, Nishijima S, Horie M, Kikuguchi C, Elisseeva O, *et al*. CNOT3 targets negative cell cycle regulators in non-small cell lung cancer development. *Oncogene*. 2019; 38: 2580-94.
- [37] Faraji F, Hu Y, Wu G, Goldberger NE, Walker RC, Zhang J, *et al*. An integrated systems genetics screen reveals the transcriptional structure of inherited predisposition to metastatic disease. *Genome Res*. 2014; 24: 227-40.
- [38] Sohn EJ, Jung DB, Lee H, Han I, Lee J, Lee H, *et al*. CNOT2 promotes proliferation and angiogenesis *via* VEGF signaling in MDA-MB-231 breast cancer cells. *Cancer Lett*. 2018; 412: 88-98.
- [39] Łabno A, Tomecki R, Dziembowski A. Cytoplasmic RNA decay pathways - Enzymes and mechanisms. *Biochim Biophys Acta*. 2016; 1863: 3125-47.
- [40] Hartley JL, Zachos NC, Dawood B, Donowitz M, Forman J, Pollitt RJ, *et al*. Mutations in TTC37 cause trichohepatoenteric syndrome (phenotypic diarrhea of infancy). *Gastroenterology*. 2010; 138: 2388-98, 2398.e1-2.
- [41] Fabre A, Charroux B, Martinez-Vinson C, Roquelaure B, Odul E, Sayar E, *et al*. SKIV2L mutations cause syndromic diarrhea, or trichohepatoenteric syndrome. *Am J Hum Genet*. 2012; 90: 689-92.
- [42] Braun JE, Truffault V, Boland A, Huntzinger E, Chang CT, Haas G, *et al*. A direct interaction between DCP1 and XRN1 couples mRNA decapping to 5' exonucleolytic degradation. *Nat Struct Mol Biol*. 2012; 19: 1324-31.
- [43] Zangari J, Ilie M, Rouaud F, Signetti L, Ohanna M, Didier R, *et al*. Rapid decay of engulfed extracellular miRNA by XRN1 exonuclease promotes transient epithelial-mesenchymal transition. *Nucleic Acids Res*. 2017; 45: 4131-41.